Julian Baker portfolio · Q2 2026
Baker Bros. Advisors LP · CIK 0001263508 ·13F filings on SEC EDGAR
In Q2 2026, Baker Bros. Advisors LP reported 84 positions worth $20B. Its largest holding was INCY at 17.5% of the portfolio, and the top 10 made up 73%. Its largest new position was FTH ($32.2M), and it sold out of ABVX.
- NEW 8
- ADD 16
- REDUCE 7
- EXIT 8
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 44 positions are grouped as one box.
Portfolio history
Q4 2025 to Q2 2026, 3 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
INCY INCYTE CORP | 17.48% | $89.93* | $121.35 | +34.9% | $3.7B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ONC BEONE MEDICINES LTD-ADR | 12.57% | $136.97* | $365.94 | +167.2% | $3.2B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMD REVOLUTION MEDICINES INC | 10.74% | $56.67 | $205.26 | +262.2% | $2.3B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDGL MADRIGAL PHARMACEUTICALS INC | 5.77% | $195.47 | $503.96 | +157.8% | $1.1B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACAD ACADIA PHARMACEUTICALS INC | 5.44% | $25.45* | $20.15 | -20.8% | $864.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KYMR KYMERA THERAPEUTICS INC | 4.97% | $37.07 | $111.79 | +201.6% | $967.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INSM INSMED INC | 4.70% | $89.19* | $114.14 | +28.0% | $1B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CELC CELCUITY INC | 4.15% | $24.80 | $79.52 | +220.6% | $629.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KOD KODIAK SCIENCES INC | 3.89% | $33.47 | $94.80 | +183.2% | $1.9B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 3.12% | $24.92 | $95.22 | +282.1% | $533.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRAX PRAXIS PRECISION MEDICINES I | 2.94% | $208.46 | $291.23 | +39.7% | $510.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALKS ALKERMES PLC | 2.63% | $26.97 | $40.52 | +50.2% | $405.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SMMT SUMMIT THERAPEUTICS INC | 2.39% | $12.42 | $16.91 | +36.1% | $554.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GRAL GRAIL INC | 1.38% | $41.82 | $140.12 | +235.0% | $564.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABCL ABCELLERA BIOLOGICS INC | 1.30% | $16.46 | $14.59 | -11.4% | $481.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 1.05% | $21.09 | $33.78 | +60.2% | $183.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IDYA IDEAYA BIOSCIENCES INC | 0.94% | $26.73 | $38.42 | +43.7% | $192.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KNSA KINIKSA PHARMACEUTICALS INTE | 0.91% | $18.84 | $74.61 | +296.1% | $211.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 0.84% | $13.76 | $36.57 | +165.7% | $172.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARWR ARROWHEAD PHARMACEUTICALS IN | 0.81% | $33.82 | $65.45 | +93.5% | $130.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IONS IONIS PHARMACEUTICALS INC | 0.81% | $74.82 | $44.65 | -40.3% | $91.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 0.75% | $15.77 | $40.60 | +157.4% | $150.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
REPL REPLIMUNE GROUP INC | 0.61% | $13.45 | $13.24 | -1.5% | $146.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 0.57% | $24.49 | $23.71 | -3.2% | $110.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STOK STOKE THERAPEUTICS INC | 0.55% | $11.09 | $26.00 | +134.4% | $86.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GLUE MONTE ROSA THERAPEUTICS INC | 0.53% | $6.13 | $11.93 | +94.7% | $51.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMTX IMMATICS NV | 0.48% | $8.87 | $8.78 | -1.0% | $83.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNLI DENALI THERAPEUTICS INC | 0.48% | $23.61 | $20.67 | -12.4% | $77.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRNX CRINETICS PHARMACEUTICALS IN | 0.44% | $41.38 | $37.42 | -9.6% | $88M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNTH DIANTHUS THERAPEUTICS INC | 0.42% | $23.41 | $88.05 | +276.1% | $75M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GPCR STRUCTURE THERAPEUTICS INC | 0.39% | $20.84 | $31.27 | +50.0% | $44.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.35% | — | — | — | $69.2M | |
RAPP RAPPORT THERAPEUTICS INC | 0.32% | $23.18 | $33.60 | +44.9% | $52M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALMS ALUMIS INC | 0.28% | $15.25 | $7.39 | -51.5% | $14.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRLD PRELUDE THERAPEUTICS INC | 0.27% | $30.14 | $3.91 | -87.0% | $39.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLAY RELAY THERAPEUTICS INC | 0.27% | $16.58 | $18.05 | +8.9% | $51M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIRM MIRUM PHARMACEUTICALS INC | 0.26% | $92.38 | $85.48 | -7.5% | $38.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCYC BICYCLE THERAPEUTICS PLC-ADR | 0.23% | $20.78 | $3.68 | -82.3% | $40.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELVN ENLIVEN THERAPEUTICS INC | 0.23% | $32.34 | $45.84 | +41.7% | $41.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLDX CELLDEX THERAPEUTICS INC | 0.22% | $29.00 | $32.41 | +11.8% | $38.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRDN VIRIDIAN THERAPEUTICS INC | 0.22% | $16.37 | $20.59 | +25.8% | $49.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DSGN DESIGN THERAPEUTICS INC | 0.19% | $9.58 | $12.57 | +31.2% | $33.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRDA ENTRADA THERAPEUTICS INC | 0.19% | $16.68 | $6.35 | -61.9% | $32.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FTH FAETH THERAPEUTICS INC | 0.16% | $25.00 | $29.74 | +19.0% | $38.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AKTS AKTIS ONCOLOGY INC | 0.16% | $17.89 | $19.47 | +8.8% | $19.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NGNE NEUROGENE INC | 0.16% | $12.31 | $27.82 | +126.0% | $27.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JBIO JADE BIOSCIENCES INC | 0.14% | $15.43 | $14.05 | -8.9% | $17.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TSHA TAYSHA GENE THERAPIES INC | 0.14% | $2.64 | $4.87 | +84.5% | $19.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RCUS ARCUS BIOSCIENCES INC | 0.13% | $27.00 | $25.83 | -4.3% | $21.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRON DISC MEDICINE INC | 0.13% | $55.66 | $65.46 | +17.6% | $22.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABSI ABSCI CORP | 0.12% | $3.49 | $10.77 | +208.6% | $23M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GENB GENERATE BIOMEDICINES INC | 0.12% | $12.50 | $15.02 | +20.2% | $21.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DBVT DBV TECHNOLOGIES SA-SPON ADR | 0.12% | $3.09 | $11.76 | +280.6% | $17.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XENE XENON PHARMACEUTICALS INC | 0.11% | $21.68 | $37.19 | +71.5% | $13.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TECX TECTONIC THERAPEUTIC INC | 0.10% | $20.51 | $23.29 | +13.5% | $14.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CERS CERUS CORP | 0.09% | $4.94* | $2.38 | -51.8% | $15.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 0.09% | $2.77 | $2.72 | -1.7% | $13.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DYN DYNE THERAPEUTICS INC | 0.09% | $19.56 | $16.11 | -17.6% | $13.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CYTK CYTOKINETICS INC | 0.09% | $85.19 | $65.91 | -22.6% | $13.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XNCR XENCOR INC | 0.09% | $18.16 | $24.95 | +37.4% | $27.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SION SIONNA THERAPEUTICS INC | 0.09% | $10.46 | $5.26 | -49.7% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NTLA INTELLIA THERAPEUTICS INC | 0.08% | $16.92 | $12.06 | -28.7% | $11.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PBLS PARABILIS MEDICINES INC | 0.07% | $27.37 | $32.29 | +18.0% | $16.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MPLT MAPLIGHT THERAPEUTICS INC | 0.07% | $17.56 | $10.19 | -42.0% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVLN AVALYN PHARMA INC | 0.06% | $32.92 | $28.49 | -13.5% | $10M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EVMN EVOMMUNE INC | 0.06% | $22.99 | $8.26 | -64.1% | $7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTX BIONTECH SE-ADR | 0.06% | $107.38 | $98.30 | -8.5% | $11.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNGX TANGO THERAPEUTICS INC | 0.05% | $31.26 | $24.95 | -20.2% | $8.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVTX AVALO THERAPEUTICS INC | 0.05% | $18.48 | $15.33 | -17.0% | $8.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SERA SERA PROGNOSTICS INC-A | 0.05% | $5.59 | $2.09 | -62.6% | $11.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VSTM VERASTEM INC | 0.05% | $4.17 | $8.05 | +93.2% | $20.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SGMT SAGIMET BIOSCIENCES INC-A | 0.04% | $7.31 | $9.88 | +35.1% | $9.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EIKN EIKON THERAPEUTICS INC | 0.04% | $10.58 | $8.04 | -24.0% | $4.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LBRX LB PHARMACEUTICALS INC | 0.03% | $15.79 | $38.38 | +143.1% | $7.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VTVT VTV THERAPEUTICS INC- CL A | 0.03% | $23.47 | $30.84 | +31.4% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Y95308105 WAVE LIFE SCIENCES LTD | 0.02% | $7.65 | $5.81 | -24.0% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TARA PROTARA THERAPEUTIC INC | 0.02% | $7.12 | $3.05 | -57.2% | $3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TCRX TSCAN THERAPEUTICS INC | 0.01% | $5.80 | $0.31 | -94.6% | $875.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMNM IMMUNOME INC | 0.01% | $21.19 | $21.51 | +1.5% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
83086J200 Skye Bioscience, Inc. | 0.01% | $4.94 | $0.69 | -86.0% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SANA SANA BIOTECHNOLOGY INC | 0.01% | $4.35 | $2.92 | -32.9% | $905.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALGS ALIGOS THERAPEUTICS INC | 0.00% | $8.66 | $5.63 | -35.0% | $467.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TYRA TYRA BIOSCIENCES INC | 0.00% | $13.85 | $21.87 | +57.9% | $232K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRZNW SURROZEN INC-CW25 | 0.00% | — | $0.02 | — | $13.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Mar 31, 2016, when our collected history starts, so the average starts from that quarter's price.
Changes in shares
Change in shares held vs Mar 31, 2026, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Mar 31, 2026 and not reported for Q2 2026.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| ABVX ABIVAX SA-ADR | 0.56% | 875,796 | $97.5M | EXIT |
| SYRE SPYRE THERAPEUTICS INC | 0.29% | 1,000,000 | $50.4M | EXIT |
| CNTA CENTESSA PHARMACEUTICALS LTD | 0.15% | 670,751 | $26.6M | EXIT |
| IMCR IMMUNOCORE HOLDINGS PLC-ADR | 0.13% | 734,397 | $22.1M | EXIT |
| CTNM CONTINEUM THERAPEUTICS INC-A | 0.11% | 1,420,838 | $18.6M | EXIT |
| ARGX ARGENX SE - ADR | 0.11% | 25,174 | $18.4M | EXIT |
| CMPS COMPASS PATHWAYS PLC | 0.07% | 2,344,720 | $13M | EXIT |
| PHVS PHARVARIS NV | 0.06% | 375,000 | $10.6M | EXIT |
SEC filings for Q2 2026
- 13F-HR 0001104659-26-097191 · accepted Aug 14, 2026, 20:16 UTC